Last reviewed · How we verify

NCT06299930

Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy

Completed Last updated 8 March 2024
What this trial tests

trial testing Neoadjuvant chemotherapy in Breast Cancer in 10,328 participants. Completed in 12 September 2023.

Timeline
22 April 2022
Primary endpoint
16 August 2023
12 September 2023

Quick facts

Lead sponsorSeoul National University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment10,328
Start date22 April 2022
Primary completion16 August 2023
Estimated completion12 September 2023
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

Adults 18 to 100, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Locoregional recurrence after neoadjuvant versus adjuvant chemotherapy based on tumor subtypes in patients with early-stage breast cancer: A multi-institutional retrospective cohort study.
    Cheun JH, Kwak Y, Kang E, Jung JJ, et al · · 2024 · cited 1× · PMID 39515238 · DOI 10.1016/j.breast.2024.103828

Verify or expand the search:

Other trials of Neoadjuvant chemotherapy

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06299930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing